FDA Panel Endorses Contrave Weight-Loss Drug

SILVER SPRING, Md. -- An FDA advisory committee has voted 13-7 that the modest weight-loss benefits of an investigational combination of naltrexone and bupropion -- marketed under the brand name Contrave -- outweigh the drug's blood pressure risk. The bupropion-naltrexone combo is the last in a trio of new weight-loss drugs that went before FDA panels this year, striving to be the latest treatment in the dwindling field of medications to fight obesity. The previous two drugs,...Full Story
Commenting on this article is closed.